CB2 Insights (CSE:CBII, OTCQB:CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, today announced that MyAccess Clinics (“MAC”) has selected CB2 Insights’ Electronic Data Capture (EDC) software to manage patient data within its growing number of medical clinics in the UK. MyAccess Clinics is a wholly-owned subsidiary of leading global medical cannabis company, Althea Group Holdings Ltd (ASX:AGH).

“The UK market continues to blossom at a rapid pace, and we are proud that our research and data technology assets continue to be sought to expedite growth in the market,” said Prad Sekar, Chief Executive Officer, CB2 Insights.  “MyAccess Clinics has an exceptional and comprehensive vision for its development in the UK’s medical cannabis market and we are excited to be a part of that effort.”


CB2 Insights’ EDC software has been used throughout the US and Canada and uses standard healthcare protocols. The system is purpose-built for medical cannabis operations and takes into account the complexity of managing data related to multiple indications across a single patient base, comorbidity in certain patient profiles, past traditional therapies and multiple consumption methods and medicine within a single treatment plan.  The system works to simplify data input and management while ensuring collection can ultimately be used to better understand the efficacy of cannabinoid therapy.  This deployment will increase both the size and scope of the Company’s data set.

Graham Woodward, MyAccess Clinics Clinical Director said “As a company, we are proud to be one of the first to service the emerging UK medical cannabis market. CB2 Insights’ software will play an integral part in  the administration of our clinics and will increase our ability to manage data, thereby improving our patient care.”

Earlier this year, CB2 Insights announced that it had been selected as the exclusive research technology platform for UK-based Drug Science and its medical cannabis pilot program.

About CB2 Insights

CB2 Insights has a mission to mainstream medical cannabis into traditional healthcare. We are a research and technology company, offering a suite of data and technology solutions as a full service clinical CRO, specializing in Phase II, III and IV, post-marketing, observational and experimental trials in a range of therapeutic areas for sponsors worldwide.

CB2 Insights helps industry stakeholders create a strong value story with Real World Evidence, generation of safety and efficacy data, operating in two segments: clinical solutions and data solutions.

For more information please visit www.cb2insights.com.

About MyAccess Clinics

MyAccess Clinics provide expert care for patients with unmet needs, which licensed medicines have failed to address, through the use of ‘specials’ medicines. ‘Specials’ are unlicensed medicines that are specifically manufactured or obtained in order to meet a patient’s individual clinical need. An example of this would be unlicensed cannabis-based products for medicinal use, which our private clinics specialize in.

MyAccess Clinics is a wholly-owned subsidiary of leading global medical cannabis company, Althea Group Holdings Ltd (ASX:AGH).

For more information please visit https://myaccessclinics.co.uk/

For additional information, please contact:

Dan Thompson – CB2 Insights
1.855.847.4999  ext 120
dan.thompson@cb2inights.com

Julia Maguire – Althea Group / The Capital Network
+61 419 815 386
julia@thecaptialnetwork.com.au

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in CB2’s filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements regarding the opportunity to provide services and software to the U.S. cannabis industry.

Although CB2 has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are subject to inconsistent legislation and regulation; change in laws; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and recreational-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. CB2 disclaims any intention or obligation to update or revise such information, except as required by applicable law, and CB2 does not assume any liability for disclosure relating to any other company mentioned herein.

No securities regulator or exchange has reviewed, approved, disapproved, or accepts responsibility for the content of this news release.

Click here to connect with CB2 Insights (CSE:CBII) for an Investor Presentation.

Source

 

Trading resumes in:

Company: Revive Therapeutics Ltd.

Keep reading... Show less

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES /

Revive Therapeutics Ltd. (” Revive ” or the ” Company “) (CSE:RVV) ( USA : RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into an amended agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (collectively, the ” Underwriters “), to increase the size of its previously announced offering of units (the ” Equity Units “) at a price of $0.50 per Equity Unit. Under the amended terms, the Underwriters have agreed to purchase, on a bought deal basis, 40,000,000 Equity Units for gross proceeds to the Company of $20,000,000 (the ” Offering “). The over-allotment option granted to the Underwriters will proportionately increase to 15% of the Offering.

Keep reading... Show less

The new dispensary brings expanded access for patients in the growing communities of Central Florida

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 77th nationwide. The new, 5,100 sq. ft. location marks the Company’s first in Summerfield expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”).

The Company announced today that its board of directors have approved a private placement of up to 15,000,000 units at a price of $.40 per unit for gross proceeds of up to $6,000,000. Each unit will consist of one common share of the Company and one share purchase warrant. Each share purchase warrant will be exercisable to purchase an additional common share at a fixed price of $.45 per share for a period of one year from closing.

Keep reading... Show less

The following issues have been halted by IIROC:

Company: Revive Therapeutics Ltd.

Keep reading... Show less